Search Results - "HILLEGE, H. L."

The fibrosis marker galectin-3 and outcome in the general population by de Boer, R. A., van Veldhuisen, D. J., Gansevoort, R. T., Muller Kobold, A. C., van Gilst, W. H., Hillege, H. L., Bakker, S. J. L., van der Harst, P.

“…  de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, Bakker SJL, van der Harst P (University of Groningen). The…”
Get full text

Telomere length loss due to smoking and metabolic traits by Huzen, J., Wong, L. S. M., Veldhuisen, D. J., Samani, N. J., Zwinderman, A. H., Codd, V., Cawthon, R. M., Benus, G. F. J. D., Horst, I. C.C., Navis, G., Bakker, S. J. L., Gansevoort, R. T., Jong, P. E., Hillege, H. L., Gilst, W. H., Boer, R. A., Harst, P.

“…Objectives Human age‐dependent telomere attrition and telomere shortening are associated with several age‐associated diseases and poorer overall survival. The…”
Get full text

Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study by Abbasi, A., Corpeleijn, E., Meijer, E., Postmus, D., Gansevoort, R. T., Gans, R. O. B., Struck, J., Hillege, H. L., Stolk, R. P., Navis, G., Bakker, S. J. L.

“…Aims/hypothesis Vasopressin plays a role in osmoregulation, glucose homeostasis and inflammation. Therefore, plasma copeptin, the stable C-terminal portion of…”
Get full text

Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators by Postmus, D, Mavris, M, Hillege, HL, Salmonson, T, Ryll, B, Plate, A, Moulon, I, Eichler, H-G, Bere, N, Pignatti, F

“…Currently, patient preference studies are not required to be included in marketing authorization applications to regulatory authorities, and the role and…”
Get full text

Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity by Hillege, H. L., Janssen, W. M. T., Bak, A. A. A., Diercks, G. F. H., Grobbee, D. E., Crijns, H. J. G. M., Van Gilst, W. H., De Zeeuw, D., De Jong, P. E.

“… Hillege HL, Janssen WMT, Bak AAA, Diercks GFH, Grobbee DE, Crijns HJGM, van Gilst WH, de Zeeuw D, de Jong PE for the PREVEND Study group (University of…”
Get full text

Sodium intake affects urinary albumin excretion especially in overweight subjects by Verhave, J. C., Hillege, H. L., Burgerhof, J. G. M., Janssen, W. M. T., Gansevoort, R. T., Navis, G. J., Zeeuw, D., Jong, P. E.

“…Objectives.  To examine the relationship between sodium intake and urinary albumin excretion, being an established risk marker for later cardiovascular…”
Get full text

Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions by Pignatti, F, Ashby, D, Brass, EP, Eichler, H-G, Frey, P, Hillege, HL, Hori, A, Levitan, B, Liberti, L, Löfstedt, RE, McAuslane, N, Micaleff, A, Noel, RA, Postmus, D, Renn, O, Sabourin, BJ, Salmonson, T, Walker, S

“…Structured frameworks for benefit‐risk analysis in drug licensing decisions are being implemented across a number of regulatory agencies worldwide. The aim of…”
Get full text

A comparison of the prognostic value of BNP versus NT-proBNP after hospitalisation for heart failure by Linssen, G. C. M., Jaarsma, T., Hillege, H. L., Voors, A. A., van Veldhuisen, D. J.

“…Aims Concentrations of circulating B‑type natriuretic peptides provide important prognostic information in heart failure (HF) patients. We directly compared…”
Get full text

Novel endotypes in heart failure: effects on guideline-directed medical therapy by Tromp, J, Ouwerkerk, W, Demissei, B G, Anker, S D, Cleland, J G, Dickstein, K, Filippatos, G, van der Harst, P, Hillege, H L, Lang, C C, Metra, M, Ng, L L, Ponikowski, P, Samani, N J, van Veldhuisen, D J, Zannad, F, Zwinderman, A H, Voors, A A, van der Meer, P

Get full text

Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial by Hillege, H.L., van Gilst, W.H., van Veldhuisen, D.J., Navis, G., Grobbee, D.E., de Graeff, P.A., de Zeeuw, D.

“…Aims Information regarding the cardiorenal axis in patients after a myocardial infarction (MI) is limited. We examined the change in renal function after a…”
Get full text

Renal function, neurohormonal activation, and survival in patients with chronic heart failure by HILLEGE, H. L, GIRBES, A. R. J, DE KAM, P. J, BOOMSMA, F, DE ZEEUW, D, CHARLESWORTH, A, HAMPTON, J. R, VAN VELDHUISEN, D. J

“…Because renal function is affected by chronic heart failure (CHF) and it relates to both cardiovascular and hemodynamic properties, it should have additional…”
Get full text

Plasma procalcitonin and risk of type 2 diabetes in the general population by Abbasi, A., Corpeleijn, E., Postmus, D., Gansevoort, R. T., de Jong, P. E., Gans, R. O. B., Struck, J., Hillege, H. L., Stolk, R. P., Navis, G., Bakker, S. J. L.

Get full text

Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study by Ouwerkerk, W, Voors, A A, Anker, S D, Cleland, J G, Dickstein, K, Filippatos, G, van der Harst, P, Hillege, H L, Lang, C C, Ter Maaten, J M, Ng, L L, Ponikowski, P, Samani, N J, van Veldhuisen, D J, Zannad, F, Metra, M, Zwinderman, A H

“…Despite clear guidelines recommendations, most patients with heart failure and reduced ejection-fraction (HFrEF) do not attain guideline-recommended target…”
Get full text

Health-related quality of life and anemia in hospitalized patients with heart failure by Kraai, I.H, Luttik, M.L.A, Johansson, P, De Jong, R.M, Van Veldhuisen, D.J, Hillege, H.L, Jaarsma, T

“…Abstract Background Anemia is a serious and highly prevalent co-morbidity in chronic heart failure (HF) patients. Its influence on health-related quality of…”
Get full text

Obesity and target organ damage: the kidney by Jong, P.E. de, Verhave, J.C, Pinto-Sietsma, S.J, Hillege, H.L

“…Obesity is a risk marker for progressive renal function loss in patients with known renal disease. There is, however, increasing evidence that obesity may also…”
Get full text

Smoking is related to albuminuria and abnormal renal function in nondiabetic persons by PINTO-SIETSMA, Sara-Joan, MULDER, Jaap, JANSSEN, Wilbert M. T, HILLEGE, Hans L, DE ZEEUW, Dick, DE JONG, Paul E

“…Smoking induces albuminuria and accelerates progression to renal failure in persons with diabetes, but little is known about the relation between smoking and…”
Get full text

Diuretic response in acute heart failure: clinical characteristics and prognostic significance by Valente, Mattia A. E., Voors, Adriaan A., Damman, Kevin, Van Veldhuisen, Dirk J., Massie, Barrie M., O'Connor, Christopher M., Metra, Marco, Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth, Cleland, John G.F., Givertz, Michael M., Bloomfield, Daniel M., Fiuzat, Mona, Dittrich, Howard C., Hillege, Hans L.

“…Aim Diminished diuretic response is common in patients with acute heart failure, although a clinically useful definition is lacking. Our aim was to investigate…”
Get full text

The reliability of different formulae to predict creatinine clearance by Verhave, J. C., Baljé‐Volkers, C. P., Hillege, H. L., De Zeeuw, D., De Jong, P. E.

“…  Verhave JC, Baljé‐Volkers CP, Hillege HL, de Zeeuw D, de Jong PE (University Medical Center Groningen, Groningen University, Institute of Drug Exploration,…”
Get full text

Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study by Diercks, G.F.H, van Boven, A.J, Hillege, H.L, Janssen, W.M.T, Kors, J.A, de Jong, P.E, Grobbee, D.E, Crijns, H.J.G.M, van Gilst, W.H

“…Aim To assess the value of microalbuminuria as an indicator of increased cardiovascular risk in a non-diabetic population. Methods and Results 7579…”
Get full text

Novel endotypes in heart failure: effects on guideline-directed medical therapy by Tromp, J, Ouwerkerk, W, Demissei, B G, Anker, S D, Cleland, J G, Dickstein, K, Filippatos, G, van der Harst, P, Hillege, H L, Lang, C C, Metra, M, Ng, L L, Ponikowski, P, Samani, N J, van Veldhuisen, D J, Zannad, F, Zwinderman, A H, Voors, A A, van der Meer, P

“…We sought to determine subtypes of patients with heart failure (HF) with a distinct clinical profile and treatment response, using a wide range of biomarkers…”
Get full text